Clinical Trial Update: Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of docetaxel and imatinib mesylate in metastatic breast cancer has completed, with results posted in May 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-05-14